Universe Pharmaceuticals (UPC) Non-Current Debt (2024 - 2026)

Universe Pharmaceuticals (UPC) posted Non-Current Debt of $2.2 million for Q1 2026, down 99.9% sequentially from $2.1 billion in Q3 2024.

Universe Pharmaceuticals (UPC) Non-Current Debt (2024 - 2026) Analysis & Trends

Universe Pharmaceuticals has reported Non-Current Debt for 2 years, with the latest figure at $2.2 million in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed N/A YoY) and the FY2024 annual result came in at $2.1 billion, changed N/A from the prior year.
Non-Current Debt eased to $2.2 million in Q1 2026 per UPC's latest filing, from $2.1 billion in the prior quarter.
Over five years, Non-Current Debt peaked at $2.1 billion in Q3 2024 and troughed at $2.1 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-8.44 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	12.09 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	27.73 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	11.61 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.85 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	130.00 Mn
10	Universe Pharmaceuticals	3.04 Mn	-26.01 Mn	-	2.17 Mn

Download Data